Pharmaceutical Manipulation of Mitochondrial F0F1‐ATP Synthase Enables Imaging and Protection of Myocardial Ischemia/Reperfusion Injury Through Stress‐induced Selective Enrichment
Advanced Science · 2024
DOI: 10.1002/advs.202307880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Zelin Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Rocket Force Medicine, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400038, China. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Myocardial Infarction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Outstanding Scientist Program of Chongqing Talent Plan.
Abstract (Originalsprache)
To rescue ischemic myocardium from progressing to myocardial infarction, timely identification of the infarct size and reperfusion is crucial. However, fast and accurate identification, as well as the targeted protection of injured cardiomyocytes following ischemia/reperfusion (I/R) injury, remain significantly challenging. Here, a near infrared heptamethine dye IR‐780 is shown that has the potential to quickly monitor the area at risk following I/R injury by selectively entering the cardiomyocytes of the at‐risk heart tissues. Preconditioning with IR‐780 or timely IR‐780 administration before reperfusion significantly protects the heart from ischemia and oxidative stress‐induced cell death, myocardial remodeling, and heart failure in both rat and pig models. Furthermore, IR‐780 can directly bind to F0F1‐ATP synthase of cardiomyocytes, rapidly decrease the mitochondrial membrane potential, and subsequently slow down the mitochondrial energy metabolism, which induces the mitochondria into a “quiescent state” and results in mitochondrial permeability transition pore inhibition by preventing mitochondrial calcium overload. Collectively, the findings show the feasibility of IR‐780‐based imaging and protection strategy for I/R injury in a preclinical context and indicate that moderate mitochondrial function depression is a mode of action that can be targeted in the development of cardioprotective reagents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Rocket Force Medicine, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400038, China.
- Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
ORCID-Profile: Zelin Chen, Xu Tan, Yu Wang, Gufang Shen, Can Zhang, Chunmeng Shi
Förderung
- National Natural Science Foundation of China
- Outstanding Scientist Program of Chongqing Talent Plan
Zitieren
APA
Chen, Z., Tan, X., Jin, T., Wang, Y., Dai, L., Shen, G., Zhang, C., Qu, L., Long, L., Shen, C., Cao, X., Wang, J., Li, H., Yue, X., & Shi, C. (2024). Pharmaceutical Manipulation of Mitochondrial F0F1‐ATP Synthase Enables Imaging and Protection of Myocardial Ischemia/Reperfusion Injury Through Stress‐induced Selective Enrichment. Advanced Science. https://doi.org/10.1002/advs.202307880
Vancouver
Chen Z, Tan X, Jin T, Wang Y, Dai L, Shen G, et al. Pharmaceutical Manipulation of Mitochondrial F0F1‐ATP Synthase Enables Imaging and Protection of Myocardial Ischemia/Reperfusion Injury Through Stress‐induced Selective Enrichment. Advanced Science. 2024. doi:10.1002/advs.202307880
BibTeX
@article{Chen2024,
author = {Chen, Zelin and Tan, Xu and Jin, Taotao and Wang, Yu and Dai, Linyong and Shen, Gufang and Zhang, Can and Qu, Langfan and Long, Lei and Shen, Chongxing and Cao, Xiaohui and Wang, Jianwu and Li, Huijuan and Yue, Xiaofeng and Shi, Chunmeng},
title = {Pharmaceutical Manipulation of Mitochondrial F0F1‐ATP Synthase Enables Imaging and Protection of Myocardial Ischemia/Reperfusion Injury Through Stress‐induced Selective Enrichment},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202307880}
}
EUVIMED